AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting risk

KALA · NASDAQ · Biotechnology

KALA BIO

Evaluates biotech AI infrastructure while preserving biologics assets for potential partners.

$0.6902

After-hours close+0.00 (+0.01%)

At close$0.6901(−15.02%)

Something off on this page? Send us feedback.

Profile

KALA BIO, Inc.KALAHealth Care

Evaluates the licensed Researgency AI platform for biotech and pharmaceutical clients while preserving MSC-S biologics assets. Future activity on KPI-012 and KPI-014 depends on partners, strategic arrangements, or additional capital.

Evaluates two business lines: the licensed Researgency platform, an on-premises AI infrastructure offering for biotechnology and pharmaceutical clients, and retained MSC-S biologics assets. Its former ophthalmology operation developed therapies for rare and severe diseases of the front and back of the eye; KPI-012 and KPI-014 are now held for potential partners. Researgency is being evaluated as a platform-as-a-service initiative.

Researgency is licensed from Younet AI and intended for secure, purpose-built deployment within client environments. Future work on KPI-012, KPI-014, and related MSC-S intellectual property depends on licensing, collaborations, other strategic arrangements, or additional capital.

Company facts

CEOAvi Minkowitz

ListedJul 20, 2017

ExchangeNASDAQ

HeadquartersArlington, MA

CountryUnited States

Employees3

CIK0001479419

ISINUS4831193010

Key statistics

Market cap$13.3M

EPS (ttm)−$10.12

P/E (ttm)−0.0682

ROE-222.3%

P/B0.0566

P/S0.00

Dividend yield—

Beta2.19vs XLV −0.77

Year to date −97.8% · Average volume (30d) 153.3K

Analysts

Price target, next 12 months$18.25+2,544.9%Median of 11 analysts · vs the Aug 28 close

ConsensusHold4 of 11 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $0.6900

High$35.00+4,972.5%

Median$18.25+2,544.9%

Low$1.50+117.4%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Target
Sep 30, 2025	Mizuho Securities	Target			$1.50
Sep 30, 2025	Mizuho	Downgrade	Outperform	Neutral
Sep 29, 2025	H.C. Wainwright	Downgrade	Buy	Neutral
Sep 29, 2025	Ladenburg Thalmann	Downgrade	Buy	Neutral
Sep 29, 2025	HC Wainwright & Co.	Downgrade	Buy	Neutral

Earnings

EPS

Estimate−$6.00

ReportedDue Nov 10, 2026

Revenue

Estimate—

ReportedDue Nov 10, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 19, 2026Q2 FY26	−$6.00	−$21.32	−255.3%	$25.0M	—	—	+0.14%
May 15, 2026Q1 FY26	−$8.50	−$0.20	+97.6%	—	—	—	−7.51%
Apr 15, 2026Q1 FY26	−$16.00	$0.08	+100.5%	—	—	—	−3.82%
Nov 19, 2025Q3 FY25	−$1.01	−$1.07	−5.9%	—	—	—	+2.50%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$0	$0	$0	$0	$0	$0
Gross profit	$0	$0	$0	−$54.0K	$0	$0
Operating income	−$10.7M	−$11.0M	−$7.2M	−$10.2M	−$1.8M	−$1.7M
Net income	−$8.9M	−$11.2M	−$7.6M	$686.0K	−$1.6M	−$1.6M
Diluted EPS	−$1.41	−$1.71	−$1.07	$0.08	−$7.00	−$2.13
Gross margin	—	—	—	—	—	—
Operating margin	—	—	—	—	—	—

Fiscal years (4-quarter sums)FY21 $11.2M · FY22 $3.9M · FY23 $0 · FY24 $0 · FY25 $0

Balance sheet, Jun 30, 2026Cash & short-term investments $7.2M · Total debt $0 · Total assets $10.6M · Shareholders' equity $9.0M

Dividends

No dividends on record.

Ownership

Institutions 0.18%34.0K sharesInsiders 0.03%6.3K sharesOther 99.79%19.30M shares

Shares outstanding 19.34M · Float 18.59M · 96.1% free float

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Oct 22, 2025	Darius Kharabi	officer: CHIEF BUSINESS OFFICER	−20,806	$0.8300
Oct 22, 2025	Romulus K. Brazzell	officer: SEE REMARKS	−46,748	$0.8300
Oct 22, 2025	Todd Bazemore	director	−47,768	$0.8300
Oct 23, 2025	Mary Reumuth	officer: CHIEF FINANCIAL OFFICER	−967	$0.8200
Oct 22, 2025	Mary Reumuth	officer: CHIEF FINANCIAL OFFICER	−32,230	$0.8300